利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

68 条记录 (耗时 0.021 秒)

    Downregulation of SPY1 by p53 as an essential component of p53-mediated effects
    32.
    发明申请
    Downregulation of SPY1 by p53 as an essential component of p53-mediated effects 审中-公开
    通过p53下调SPY1作为p53介导的作用的重要组成部分

    公开(公告)号：US20120082655A1

    公开(公告)日：2012-04-05

    申请号：US13137440

    申请日：2011-08-16

    申请人： Espanta Jalili ,  Dorota Lubanska ,  Lisa Porter

    发明人： Espanta Jalili ,  Dorota Lubanska ,  Lisa Porter

    IPC分类号： A61K38/45 ,  A61P35/00 ,  A61K38/48 ,  C12N5/071 ,  A61K38/17

    CPC分类号： G01N33/57484 ,  A61K38/1758 ,  G01N2333/4748 ,  A61K2300/00

    摘要： The present invention relates to a novel method of treating or preventing cancer as well as a novel method for diagnosing or monitoring cancer, wherein the cancer is caused by delayed entry to cellular senescence. More particularly, the present invention relates to a novel method of treating or preventing cancer, comprising a step of administering an agent selected to degrade, inhibit or downregulate Spy1 in a cell. The present invention also relates to a novel method of diagnosing or monitoring cancer, comprising the steps of treating a cell with UV radiation and measuring amounts of a Spy1 protein and a p53 protein, or a ratio thereof.

    摘要翻译： 本发明涉及治疗或预防癌症的新方法以及用于诊断或监测癌症的新方法，其中癌症是由延迟进入细胞衰老引起的。 更具体地说，本发明涉及一种治疗或预​​防癌症的新方法，包括施用选择降解，抑制或下调细胞中Spy1的药剂的步骤。 本发明还涉及诊断或监测癌症的新方法，包括以下步骤：用UV辐射处理细胞并测量Spy1蛋白和p53蛋白的量或其比例。

    Use of Antibody Conjugates
    34.
    发明申请
    Use of Antibody Conjugates 审中-公开
    抗体缀合物的使用

    公开(公告)号：US20100143358A1

    公开(公告)日：2010-06-10

    申请号：US12523438

    申请日：2008-01-22

    申请人： Richard H. Weisbart

    发明人： Richard H. Weisbart

    IPC分类号： A61K39/395 ,  A61P35/00

    CPC分类号： C07K16/44 ,  A61K38/1758 ,  A61K47/6851 ,  C07K2317/14 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/77 ,  C07K2317/92 ,  C07K2319/01 ,  C07K2319/30

    摘要： Provided herein are methods for inducing growth arrest or apoptosis in cancer cells in a subject. Further provided are methods of inhibiting or treating metastasis of a cancer cell in a subject. The methods involve administering to the subject an antibody conjugate containing an antibody, variant thereof, or functional fragment thereof having binding specificity of the antibody as produced by the hybridoma having ATCC accession number PTA 2439 and a biologically active molecule. The antibody (e.g., mAb 3E10) variant or functional fragment thereof provides for the in vivo transduction of the conjugate to the nucleus of mammalian cells, where the conjugated biologically active molecule may exert its effect. In particular embodiments, the antibody conjugate comprises a single chain Fv fragment of an antibody having the binding specificity of mAb 3E10 produced by ATCC PTA 2439, conjugated to p53.

    摘要翻译： 本文提供了用于诱导受试者的癌细胞中生长停滞或细胞凋亡的方法。 还提供了抑制或治疗受试者中癌细胞转移的方法。 所述方法包括向受试者施用含有抗体的抗体缀合物，其具有由具有ATCC登录号PTA 2439和生物活性分子的杂交瘤产生的具有抗体结合特异性的抗体，其变体或其功能片段。 抗体（例如，mAb 3E10）变体或其功能片段提供缀合物向哺乳动物细胞核的体内转导，其中缀合的生物活性分子可发挥其作用。 在具体实施方案中，抗体缀合物包含具有与p53缀合的ATCC PTA 2439产生的mAb 3E10的结合特异性的抗体的单链Fv片段。

    Probiotic method and composition for maintaining a healthy vaginal microbiome
    37.
    发明授权
    Probiotic method and composition for maintaining a healthy vaginal microbiome 有权

    公开(公告)号：US12005085B2

    公开(公告)日：2024-06-11

    申请号：US18232433

    申请日：2023-08-10

    申请人： Seed Health, Inc.

    发明人： Sheri Simmons ,  Tye Jensen ,  Joseph E. Kovarik

    IPC分类号： A61K35/74 ,  A61K31/58 ,  A61K31/715 ,  A61K35/00 ,  A61K38/17

    CPC分类号： A61K35/74 ,  A61K31/58 ,  A61K31/715 ,  A61K38/1709 ,  A61K38/1758 ,  A61K2035/11

    摘要： A method to reduce the likelihood of a dysbiosis of the vaginal microbiome in an individual employing a probiotic method and composition for maintaining a healthy vaginal microbiome, with particular embodiments including a bacterial formulation of at least two live bacteria selected from the group consisting of L. reuteri, L johnsonii and L. crispatus, and at least one prebiotic having glycogen as a component thereof. The bacterial formulation is administered to an individual's vagina in an amount sufficient for the bacterial formulation to generate an amount of tryptophan metabolites sufficient to act as aryl hydrocarbon receptor (AHR) agonists, thereby reducing inflammation in the individual's vagina. Certain embodiments include increasing the production of SCFAs in the individual's gut microbiome, while reducing the production of SCFAs in the individual's vagina and introducing ammonia oxidizing microorganisms to the individual's vagina.